Low-Dose Colchicine After Myocardial Infarction With Genetic Screening

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for new treatment regimens to reduce the risk of recurrent cardiovascular events and inflammation in patients after myocardial infarction, as existing treatments like canakinumab have shown mixed results and potential side effects, while colchicine's efficacy in larger placebo-controlled trials is unclear.

Innovation Solution

A clinical trial (COLCOT) was conducted to evaluate the effects of low-dose colchicine (0.5 mg daily) in patients post-myocardial infarction, identifying genetic markers to predict individual responses and reducing morbidity through colchicine administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If canakinumab is used to reduce cardiovascular events, then the risk of cardiovascular events decreases by 15%, but the incidence of fatal infections increases

Engineering Contradiction:

Improvecardiovascular event preventionVSAvoidfatal infections

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent substitutes the expensive monoclonal antibody canakinumab with inexpensive colchicine, an orally administered drug with a long history of safe use. This replacement eliminates the serious side effect profile of canakinumab while maintaining anti-inflammatory efficacy through a different mechanism of action targeting the inflammasome pathway

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent changes the therapeutic parameter from high-cost biologic intervention to low-cost oral medication, fundamentally altering the risk-benefit profile. Colchicine at low doses (0.5-1.5 mg daily) provides sustained anti-inflammatory effects without the immunosuppression and infection risks associated with canakinumab

Inventive Principle:

Principle #35Parameter changes

2Reliability

If colchicine is used at higher doses to treat inflammatory conditions, then anti-inflammatory effects increase, but the risk of gastrointestinal side effects and toxicity increases

Engineering Contradiction:

Improveanti-inflammatory effectVSAvoidgastrointestinal side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter optimization by using low doses of colchicine (0.5-1.5 mg daily) rather than higher doses traditionally used for acute gout or familial Mediterranean fever. This dose range provides sufficient anti-inflammatory efficacy for secondary prevention in coronary artery disease while minimizing gastrointestinal toxicity and other adverse effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses a partial dose of colchicine that is sufficient to inhibit the inflammasome pathway and reduce cardiovascular inflammation without reaching doses that cause significant toxicity. This partial action approach achieves the therapeutic goal with an improved safety margin

Inventive Principle:

Principle #16Partial or excessive action

3Reliability

If statins are administered to patients after myocardial infarction, then cardiovascular protection is improved, but the risk of myopathy increases

Engineering Contradiction:

Improvecardiovascular protectionVSAvoidmyopathy risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines statin therapy with low-dose colchicine to achieve synergistic cardiovascular protection. The two drugs work through different mechanisms (statins via HMG-CoA reductase inhibition and colchicine via inflammasome inhibition), providing complementary benefits while the low dose of colchicine minimizes additive myopathy risk

Inventive Principle:

Principle #5Merging (Combining)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Colchicine significantly lowers the risk of ischemic cardiovascular events and severe conditions without increasing septic shock, with no myopathy risk, even with statin use, and identifies genetic variants for personalized treatment.

Implementation Method 1

Its mechanism of action is through the inhibition of tubulin polymerization and microtubule generation

Methodology Applied

Scientific EffectTubulin polymerization inhibition:

Data Source

PatentUS12514832B2Methods for using low-dose colchicine after myocardial infarction

Publication Date: 2026.01.06 INST DE CARDIOLOGIE DE MONTREAL

AI summary

The invention features methods of treating a patient after having a myocardial infarction including administering colchicine to a patient determined to have a genetic variant in the genome that is indicative of the patient benefiting from colchicine administration or not to have a genetic variant in the genome that is that is indicative of the patient suffering a gastrointestinal disorder following colchicine administration.